Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study

Lu Gao,Li Yang,Shiyuan Zhou,Wenjuan Zhu,Yue Han,Suning Chen,Shengli Xue,Ying Wang,Huiying Qiu,Depei Wu,Xiaojin Wu
DOI: https://doi.org/10.1186/s13287-024-03640-4
2024-01-31
Stem Cell Research & Therapy
Abstract:Elderly patients with acute myeloid leukemia or myelodysplastic syndromes (AML/MDS) have historically had poor prognoses. However, there has been a recent increase in the use of allogenic hematopoietic stem cell transplantation (allo-HSCT) are in this patient population. Nevertheless, the optimal choice of donor type for the patients remains an unmet need. Limited data exist on the use of allo-HSCT in elderly patients with AML/MDS from China. To better understand and optimize the selection of donor type for the elderly patients, particularly for those with refractory or relapsed disease, in comparison with the previous studies in the US and Europe.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?